A new artificial intelligence-powered cancer detection tool is under review by the Food and Drug Administration and could become the first device of its kind approved in the U.S., according to a Newsweek report.
The company behind the technology said it hopes to launch the tool next year if it receives regulatory clearance.
C the Signs is designed to help clinicians identify patients at risk of cancer by analyzing existing medical records, including physician notes, prescriptions and test results, without requiring additional scans or imaging.
The goal is to detect cancer at an earlier and more treatable stage.
Dr.
